is kratom dangerous?

is kratom an opioid?

last verified: august 18, 2026. kratom acts on opioid receptors. that single pharmacological fact drives nearly everything else on this page: the tolerance, the dependence, the opioid-type withdrawal syndrome, and the additive danger when it is taken with other sedating drugs or with drugs cleared by the same CYP enzymes.

it is not a poppy-derived opiate, and it is not scheduled as an opioid under US federal law [5]. but "not scheduled" describes a regulatory situation, not a pharmacology. the practical mistake is filing kratom mentally under herbal supplement rather than under opioid-receptor agonist — because the first category comes with an expectation of harmlessness that the second does not, and it is that expectation which leads people into daily use without ever deciding to.

does kratom work for anxiety, depression, or pain?

no controlled trial has shown that it does. a systematic review covering everything published on kratom and mental health between 1960 and 2017 found only observational and self-report evidence — no controlled trials of any kind [1]. what that literature does contain is consistent self-reported use for mood enhancement, anxiety relief and as an opioid substitute, sitting directly alongside documented dependence and withdrawal that some users describe as highly uncomfortable.

this is worth stating precisely, because "no evidence it works" is routinely misread as "evidence it does nothing". it is neither. it means that if you are taking kratom for depression, anxiety, pain or opioid withdrawal, no one has run the study that would tell you whether it helps — while the studies that do exist describe the ways it can hurt.

what is the one controlled trial, and what did it actually test?

the entirety of the controlled human evidence for kratom is a 2020 randomised, placebo-controlled, double-blind study in 26 Malaysian men who had been using kratom daily for about six years [2]. after a single kratom decoction, cold-pressor pain tolerance roughly doubled — 11.2 seconds to 24.9 seconds, p=0.02 — with no change after placebo, and no withdrawal signs across 10 to 20 hours of abstinence.

it is a genuinely useful study and it was independently funded by an NIH grant, which puts it above most of what surrounds it. it is also a single dose, in 26 people, all of them already habituated, measuring how long they could hold a hand in cold water. it says nothing about mental health outcomes, nothing about long-term safety, and nothing about what happens to someone who starts from zero. an entire consumer market rests on this.

why is the survey everyone cites not evidence of safety?

the number that circulates most is 8,049 — the sample size of a 2017 anonymous online survey of US kratom users [4]. most respondents were middle-aged, and most reported using kratom to self-treat pain (68%) or emotional and mental conditions (66%). adverse effects, mainly nausea and constipation, were dose-dependent and appeared chiefly at 5 g or more taken 22 or more times per week.

the problem is structural, not incidental. the survey was funded by the American Kratom Association, a pro-kratom advocacy organisation, and respondents were recruited through its channels. a self-selected sample of satisfied current users, gathered by an advocacy group, cannot measure efficacy, cannot measure how often dependence occurs, and by construction cannot capture harms among the people who already stopped — which is precisely the group any safety question is about. we record it as industry-funded for that reason and rate it accordingly.

does kratom cause dependence and withdrawal?

yes, and this is the best-supported claim on the page. a systematic review of the kratom-withdrawal literature, combined with the authors’ own clinical cases, concluded that chronic use produces dependence, tolerance and an opioid-like withdrawal syndrome on cessation — including in people with no opioid history — and that clinicians increasingly encounter these presentations [3]. the withdrawal picture is the familiar opioid one: muscle aches, insomnia, irritability, craving.

one caveat matters and cuts in an unusual direction. because the evidence base is case reports and case series rather than controlled cohorts, it establishes that withdrawal happens without establishing how often. that is a real limitation. it is not, however, reassurance — case-series evidence tends to capture the severe end and miss the rest, so the unknown is the rate, not the reality.

what else has been documented?

alongside dependence, the surveillance and regulatory record includes liver injury, seizures, and neonatal withdrawal following use in pregnancy. marketed products have been found contaminated with salmonella and adulterated with heavy metals. poison-centre calls and kratom-involved overdose deaths — usually in combination with other drugs — have risen sharply in the US [5].

and because kratom is unregulated for content, alkaloid potency varies widely between batches and between product types. concentrated 7-hydroxymitragynine extracts, sold as shots and tablets rather than leaf powder, are substantially more potent than leaf products; that gap is why the FDA moved in 2025 to recommend federal scheduling of the concentrates specifically. two products both labelled kratom can be very different exposures.

these are surveillance and regulatory findings rather than results from a single numbered trial, and we present them as such rather than dressing them up as trial data [5][6].

is kratom legal?

federally, kratom is not scheduled under the Controlled Substances Act. the DEA announced its intent to schedule mitragynine in 2016 and withdrew that notice after public comment. the FDA has never approved kratom for any medical use, does not regard it as a lawful dietary supplement ingredient, and has issued import alerts, warning letters and repeated public warnings [5].

state law diverges sharply from federal. several states — including Alabama, Arkansas, Indiana, Rhode Island, Vermont and Wisconsin — have banned it. and the federal position is not static: in 2025 the FDA moved to recommend scheduling concentrated 7-hydroxymitragynine products. if the legal question matters to you, check your own state’s current statute rather than a listicle, because this is a moving target.

what should I do if I already use kratom?

tell a prescriber — how much, how often, and for how long. that is not a moral instruction; it is a practical one, because kratom interacts with other sedating drugs and with drugs metabolised by CYP enzymes, and because a clinician who does not know you take it cannot interpret your liver tests or plan around your withdrawal risk.

if you have been using daily and want to stop, do not improvise a taper from a forum. the withdrawal literature is case reports rather than controlled studies, so there is no validated protocol to copy — which is exactly why the question belongs with someone who can manage opioid-type withdrawal properly. and if kratom has been standing in for treatment of pain, anxiety or depression, the underlying condition is still there and is treatable with things that have actually been tested.